Kyverna Therapeutics appoints Greg Martini as CFO (KYTX:NASDAQ)
· seekingalpha.com
Kyverna Therapeutics appoints Greg Martini CFO as it readies miv-cel (KYV-101) for potential launch and stiff person syndrome approval.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...